LakePharma and NJ Bio partner on ‘one-stop’ ADC manufacturing service

By Vassia Barba

- Last updated on GMT

(Image: Getty/extender01)
(Image: Getty/extender01)

Related tags Antibody drug conjugates antibody-drug conjugates Antibody Contract manufacturing

Antibody-focused service providers merge their offerings to create a ‘seamless workflow’ on antibody-drug conjugates to help save developers’ time and costs.

LakePharma, a US-based biologics contract research, development, and manufacturing organization (CRDMO), will work jointly with NJ Biopharmaceuticals, a provider of chemistry and biology services, to create a streamlined antibody-drug conjugate (ADC) development service.

Specifically, the agreement will see LakePharma manufacture and provide antibodies as starting materials for ADC development, which will be carried out by NJ Bio, in order to support drug developers working on such treatments.

This joint service, leveraging the capabilities of both companies in their field, is expected to create a ‘seamless workflow’ for clients, from initial antibody discovery to the production of the drug conjugates in a manner “significantly more efficient both in time and expense,”​ LakePharma stated.

Commenting on the partnership, Nareshkumar Jain, CEO of NJ Bio, stated that the partnership will expand and add value to the ADC services that the companies currently provide, creating cost-effective solutions through the provision of complementary service offerings.

The therapeutic potential of ADCs and their uptake from the industry has seen several companies establishing partnerships, such as AstraZeneca with Daiichi Sankyo​ last year, as well as investment in capabilities, such as that of Lonza​ – which stated that it was preparing for a ‘new wave’ of ADC therapies.

Related news

Show more

Related products

show more

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Thermo Fisher Scientific - Process Liquid Preparation Services | 21-Feb-2023 | Technical / White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

INDENA ALWAYS AT THE FOREFRONT FOR CDMO SERVICES

INDENA ALWAYS AT THE FOREFRONT FOR CDMO SERVICES

Indena | 25-Oct-2022 | Technical / White Paper

Indena is well known in the space of naturally derived molecules, with a know-how developed over its one hundred year history. At the same time, the company...

Flexible Filling Solution for CMOs

Flexible Filling Solution for CMOs

Single Use Support GmBH | 18-May-2022 | Insight Guide

Achieving flexibility requires modularity of technologies.

CMOs and CDMOs aspire to be flexible for multiple applications. Efficient automated...

Related suppliers

Follow us

Products

View more

Webinars